Related Experiment Video
Updated: Jul 10, 2025
07:10
Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
4.3K
NSAIDs do not reduce severity among post-ERCP pancreatitis patients
Bara El Kurdi1, Zaid Imam2, Abdulrahman Abonofal3
1Department of Internal Medicine East Tennessee State University, Johnson City, TN, USA; Division of Gastroenterology and Hepatology, University of Texas Health at San Antonio, TX, USA.
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) reduce the overall incidence of post-ERCP pancreatitis (PEP). However, NSAIDs do not affect the severity of PEP among patients who develop it, indicating a need for alternative strategies.
Area of Science:
- Gastroenterology and Endoscopy
- Pharmacology and Therapeutics
- Clinical Trial Analysis
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are widely studied for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP).
- The effect of NSAIDs on moderate to severe PEP (MSPEP) remains unclear despite their known impact on overall PEP rates.
- Understanding NSAIDs' role in MSPEP is crucial for optimizing patient care after ERCP procedures.
Approach:
- Conducted a systematic review and meta-analysis of randomized trials investigating NSAIDs for PEP prevention.
- Analyzed pooled prevalence and Odds Ratios for PEP and MSPEP in NSAID-treated versus control groups.
- Surveyed physicians' understanding of NSAIDs' impact on MSPEP before and after reviewing study results.
Key Points:
- NSAIDs significantly reduced the overall incidence of PEP (OR 0.598) and the overall burden of MSPEP (OR 0.59) in patients undergoing ERCP.
- NSAIDs did not alter the proportion of MSPEP among patients who developed PEP (p=0.658).
- Rectal NSAIDs (indomethacin, diclofenac) were effective in reducing PEP but not MSPEP incidence.
Conclusions:
- NSAIDs, particularly rectal formulations, prevent the initiation of PEP by reducing the overall incidence.
- However, NSAIDs do not influence the severity of PEP in patients who develop the condition.
- Alternative therapeutic strategies are necessary to reduce MSPEP in patients who develop PEP post-ERCP.
Related Concept Videos
01:30Acute Pancreatitis II: Clinical Manifestations and Management
130
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
130
01:26Endoscopic Procedures V: ERCP
272
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...
Patient...
272
01:29Chronic Pancreatitis II: Collaborative Care
94
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
94
01:24Chronic Pancreatitis I: Introduction
90
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
90
01:26Peptic Ulcer Disease IV: Management
95
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
452
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
452